Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 5/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | F2RL3 | Q96RI0 | 9/20 | 0.40 |
| ▸ | NPC1 | O15118 | 4/20 | 0.37 |
| ▸ | RAB9A | P51151 | 4/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.37 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.37 |
| ▸ | RELA | Q04206 | 2/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12566087 | 0.83 | L3MBTL1 (0.41) | L3MBTL1TP53MAPTF2RL3NPC1 | |
| SCHEMBL15605672 | 0.75 | TP53 (0.58) | TP53MAPTF2RL3NPC1RAB9A | |
| SCHEMBL23641542 | 0.74 | L3MBTL1 (0.39) | L3MBTL1F2RL3SMN1; SMN2 | |
| SCHEMBL452295 | 0.74 | F2RL3 (0.46) | TP53F2RL3NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL8686099 | 0.73 | F2RL3 (0.40) | TP53F2RL3NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL12714463 | 0.73 | F2RL3 (0.63) | TP53MAPTF2RL3NPC1RAB9A | |
| SCHEMBL21761041 | 0.70 | F2RL3 (0.39) | TP53F2RL3NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL12616125 | 0.68 | L3MBTL1 (0.44) | L3MBTL1TP53MAPTNPC1RAB9A | |
| SCHEMBL13996095 | 0.68 | TP53 (0.50) | TP53MAPTF2RL3NPC1RAB9A | |
| SCHEMBL21760588 | 0.67 | F2RL3 (0.36) | F2RL3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020040104-A1 | BICYCLIC HETEROAROMATIC RING DERIVATIVE | 杏林製薬株式会社 | 2020-02-27 | — | — | WO | disclosed |
| US-20130071352-A1 | 5,5-FUSED ARYLENE OR HETEROARYLENE HEPATITIS C VIRUS INHIBITORS | IDENIX PHARMACEUTICALS, INC. (US) | 2013-03-21 | — | — | US | disclosed |
| US-8362068-B2 | 5,5-fused arylene or heteroarylene hepatitis C virus inhibitors | IDENIX PHARMACEUTICALS, INC. (US) | 2013-01-29 | — | — | US | disclosed |
| US-20120252721-A1 | METHODS FOR TREATING DRUG-RESISTANT HEPATITIS C VIRUS INFECTION WITH A 5,5-FUSED ARYLENE OR HETEROARYLENE HEPATITIS C VIRUS INHIBITOR | IDENIX PHARMACEUTICALS, INC. (US) | 2012-10-04 | — | — | US | disclosed |
| US-20110150827-A1 | 5,5-FUSED ARYLENE OR HETEROARYLENE HEPATITIS C VIRUS INHIBITORS | IDENIX PHARMACEUTICALS, INC. (US) | 2011-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130071352-A1 | 5,5-FUSED ARYLENE OR HETEROARYLENE HEPATITIS C VIRUS INHIBITORS | HAVCR2, CYP3A5, CYP2E1 | L3MBTL1 4016/4885TP53 1088/4885MAPT 4191/4885 |
| US-20110150827-A1 | 5,5-FUSED ARYLENE OR HETEROARYLENE HEPATITIS C VIRUS INHIBITORS | HAVCR2, CYP3A5, CYP2E1 | L3MBTL1 4016/4885TP53 1088/4885MAPT 4191/4885 |
| US-20120252721-A1 | METHODS FOR TREATING DRUG-RESISTANT HEPATITIS C VIRUS INFECTION WITH A 5,5-FUSED ARYLENE OR HETEROARYLENE HEPATITIS C VIRUS INHIBITOR | HAVCR2, CYP3A5, CYP7A1 | L3MBTL1 3088/4885TP53 2238/4885MAPT 4276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.